IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report)‘s stock had its “overweight” rating restated by Cantor Fitzgerald in a ...

Fintel reports that on January 13, 2025, Cantor Fitzgerald initiated coverage of Camtek (NasdaqGM:CAMT) with a Neutral ...

Cantor Fitzgerald raised the firm’s price target on MicroStrategy (MSTR) to $613 from $581 and keeps an Overweight rating on the shares.

Eric Johnston, Cantor Fitzgerald chief equity and macro strategist, joins 'Money Movers' to discuss Johnston's thesis for ...

The Securities and Exchange Commission charged Cantor Fitzgerald with violating laws related to disclosures by so-called blank-check companies before they raise money from the public. Cantor ...

Cantor Fitzgerald downgraded Intra-Cellular (ITCI) to Neutral from Overweight with a price target of $132, down from $135, after Johnson & ...

Cantor Fitzgerald is charged with violating antifraud and proxy provisions. Former Comtech CEO is charged with insider trading ahead of negative earnings. The Securities and Exchange Commission on ...

Cantor Fitzgerald Large Cap Focused Fund earns an Above Average Process Pillar rating. The most substantial contributor to the rating is the parent firm's five-year risk-adjusted success ratio of 90%.

WASHINGTON, Dec 12 (Reuters) - Wall Street brokerage Cantor Fitzgerald has agreed to pay a $6.75 million penalty to settle Securities and Exchange Commission charges that it misled investors in ...

Cantor Fitzgerald assumed coverage on shares of Voyager Therapeutics (NASDAQ:VYGR – Free Report) in a research note published on Friday morning, Marketbeat reports. The firm issued an overweight ...

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, commercial-stage biotechnology company with two approved ...

Cantor Fitzgerald International Eq Fund earns an Above Average Process Pillar rating. The primary contributor to the rating is the parent firm's five-year risk-adjusted success ratio of 90%.